SBI Securities’s Ascendis Pharma A/S ASND Stock Holding History

SBI Securities’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$800	Hold	3	–	–	﹤0.01%	2883
2026 Q1	$686	Sell	3 -1	-25%	-$224	﹤0.01%	2784
2025 Q4	$853	Hold	4	–	–	﹤0.01%	2701
2025 Q3	$795	Buy	4 +1	+33%	+$187	﹤0.01%	2789
2025 Q2	$518	Hold	3	–	–	﹤0.01%	2951
2025 Q1	$468	Buy	+3	New	+$429	﹤0.01%	2894

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SBI Securities's ASND Position: Q2 2026 in Review

SBI Securities held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 3 shares worth $800. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

SBI Securities first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. The position peaked at $853 in Q4 2025. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

SBI Securities held 3 shares of Ascendis Pharma A/S worth $800 as of Q2 2026.
SBI Securities left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2883 holding.
SBI Securities first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
SBI Securities's Ascendis Pharma A/S position peaked at $853 in Q4 2025.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.